businesspress24.com - Linkage Biosciences Adds to Board Leadership
 

Linkage Biosciences Adds to Board Leadership

ID: 1316513

(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 11/07/14 -- Linkage Biosciences, a leading manufacturer of tissue transplantation diagnostic products, announced the election of Mr. Lewis J. Stuart to the company''s Board of Directors. The election reflects Linkage''s continued focus on expansion in both domestic and international markets.

Mr. Stuart has more than 30 years of global healthcare commercial experience across multiple sectors including oncology, cardiovascular, and infectious disease. Currently, Mr. Stuart is Vice-President of Sales and Marketing at Genomic Health, Inc., a leader and pioneer in molecular oncology diagnostics. Prior to Genomic Health, Mr. Stuart served as President and General Manager of Phenogen Sciences, a North American subsidiary of Australia-based, Genetic Technologies, Inc. Mr. Stuart spent over eight years in several commercial roles at CV Therapeutics, now a division of Gilead Sciences, and has held senior leadership positions at both Pfizer and Bristol Myers Squibb, notably leading the launch of Viracept, a lifesaving treatment for HIV/AIDS.

"Lewis brings an extensive commercial leadership background to the Board at an important time in our development," said Zachary Antovich, CEO of Linkage Biosciences. "We look forward to benefiting from Lewis'' insights as we execute our growth initiatives."

About Linkages Biosciences
Linkage Biosciences, Inc. is a molecular diagnostics company developing and marketing products that dramatically improve and expedite complex genetic testing. LinkS?q™, the company''s HLA testing product line, is used in immunogenetics research and histocompatibility testing. The company is headquartered in South San Francisco, California. To learn more please visit .

Copyright 2014. Linkage Biosciences, Inc. All rights reserved.
Linkage Biosciences and LinkS?q are trademarks of Linkage Biosciences, Inc.






Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 Immunotherapies to Enhance Anti-Tumor Treatments in Melanoma
Atossa Genetics to Announce Third Quarter 2014 Financial Results and Provide a Company Update on Wednesday November 12, 2014
Bereitgestellt von Benutzer: Marketwired
Datum: 07.11.2014 - 07:00 Uhr
Sprache: Deutsch
News-ID 1316513
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

SAN FRANCISCO, CA


Phone:

Kategorie:

Biotech


Anmerkungen:


Diese Pressemitteilung wurde bisher 130 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Linkage Biosciences Adds to Board Leadership
"
steht unter der journalistisch-redaktionellen Verantwortung von

Linkage Biosciences (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Linkage Biosciences



 

Who is online

All members: 10 565
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 74


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.